- Home
- SMBK vs RAPP Comparison
SMBK vs RAPP Comparison
Compare SMBK & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- RAPP
- Stock Information
- Founded
- SMBK N/A
- RAPP 2022
- Country
- SMBK United States
- RAPP United States
- Employees
- SMBK N/A
- RAPP N/A
- Industry
- SMBK Major Banks
- RAPP
- Sector
- SMBK Finance
- RAPP
- Exchange
- SMBK Nasdaq
- RAPP Nasdaq
- Market Cap
- SMBK 553.9M
- RAPP 450.0M
- IPO Year
- SMBK N/A
- RAPP 2024
- Fundamental
- Price
- SMBK $35.48
- RAPP $14.53
- Analyst Decision
- SMBK Buy
- RAPP Strong Buy
- Analyst Count
- SMBK 5
- RAPP 2
- Target Price
- SMBK $34.40
- RAPP $35.00
- AVG Volume (30 Days)
- SMBK 65.9K
- RAPP 154.2K
- Earning Date
- SMBK 07-21-2025
- RAPP 08-07-2025
- Dividend Yield
- SMBK 0.90%
- RAPP N/A
- EPS Growth
- SMBK 44.84
- RAPP N/A
- EPS
- SMBK 2.26
- RAPP N/A
- Revenue
- SMBK $171,664,000.00
- RAPP N/A
- Revenue This Year
- SMBK $20.95
- RAPP N/A
- Revenue Next Year
- SMBK $9.48
- RAPP N/A
- P/E Ratio
- SMBK $15.65
- RAPP N/A
- Revenue Growth
- SMBK 16.34
- RAPP N/A
- 52 Week Low
- SMBK $24.33
- RAPP $6.43
- 52 Week High
- SMBK $37.72
- RAPP $29.74
- Technical
- Relative Strength Index (RSI)
- SMBK 71.72
- RAPP N/A
- Support Level
- SMBK $35.30
- RAPP N/A
- Resistance Level
- SMBK $35.99
- RAPP N/A
- Average True Range (ATR)
- SMBK 0.81
- RAPP 0.00
- MACD
- SMBK 0.23
- RAPP 0.00
- Stochastic Oscillator
- SMBK 87.30
- RAPP 0.00
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.